title: [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies].
abstract: OBJECTIVE
  Definition of homogeneous tumor groups of oligodendrogliomas or oligo-astrocytomas is a basic condition for an adequate evaluation and comparison of the results of treatments in patients from various institutions. However, increasing discordances are observed in the histological diagnosis of these tumors. The main goal of this study is to assess whether, for retrospective studies, MRI data may serve as a common basis for encompassing asymmetry in diagnosis established according to the WHO or Ste-Anne (SA) classification.
  
  
  METHODS
  This study included 251 adult patients in whom a SA grade A or B oligodendroglioma or oligo-astrocytoma was newly diagnosed at our institution from 1984 to 2003. Routine histological preparations and post-contrast preoperative MRI/CT-scan were simultaneously reviewed in order to assess the impact on survival of the following features: presence or absence of a polymorphous or gemistocytic astrocytic component, of necrosis and of contrast enhancement (CH); endothelial hyperplasia (EH) assessed as absent, present minor (HE+) or (HE++) when conform to the threshold of HE defined in the SA grading system of oligodendrogliomas. The tumors were graded A: no CH and no EH; in B: CH and /or HE++, and A/B: EH + but no CE.
  
  
  RESULTS
  70.1% of the tumors were classified as "pure" oligodendroglioma, 19.5% as "polymorphous oligo-astroastrocytoma" and 10.3% as "gemistocytic oligo-astrocytoma". In grade A, or B tumors, the presence of a polymorphous or a gemistocytic component had no significant influence on survival; however respectively 53% and 65% of these tumours versus 32% of "pure" oligodendrogliomas were grade B at the time of diagnosis. In either histological subtypes, survival was not significantly different when HE was absent or minor (HE+). After regrouping of the histological subtypes and of the tumors with HE+ or absent, the series included 153 oligodendrogliomas grade A and 98 grade B. Survival in patients with grade A versus grade B tumors was respectively 142 versus 52 months (p<0.0001). In grade B tumors, necrosis had no significant influence on survival. Ring-shaped contrast enhancement surrounding large foci of necrosis was observed in only 4 cases. In tumors with or without CE, patient survival was respectively 148 versus 40 months (p<0.0001). On post contrast MRI done in 235 patients, only 7 tumors (3%) were grade A/B (EH++ but no CH).
  
  
  CONCLUSIONS
  From these results and our previous observation that, according to the SA classification of gliomas, only oligodendrogliomas or oligo-astrocytomas may not show CE, we propose that for retrospective studies: 1) tumors diagnosed according to the Ste-Anne classification as oligodendroglioma or oligo-astrocytoma be regrouped in a unique category, 2) independent of their histological type and grade according to the WHO, gliomas that do not show CE be regrouped with SA oligodendrogliomas grade A, 3) concerning gliomas that show CE on MRI: oligodendrogliomas or oligo-astrocytomas WHO grade II or III, as well as WHO secondary glioblastomas or glioblastomas with an oligodendroglial component, be regrouped with SA oligodendrogliomas grade B; however tumors that show ring-like CE surrounding large foci of necrosis and finger-like "peritumoral" edema should be excluded or analysed separately.
authors.affiliation: Service de Pathologie, Centre Hospitalier Sainte-Anne, Paris. c.daumas@ch-sainte-anne.fr
authors.forename: C
authors.initials: C
authors.lastname: Daumas-Duport
authors.forename: M
authors.initials: M
authors.lastname: Koziak
authors.forename: C
authors.initials: C
authors.lastname: Miquel
authors.forename: F
authors.initials: F
authors.lastname: Nataf
authors.forename: A
authors.initials: A
authors.lastname: Jouvet
authors.forename: P
authors.initials: P
authors.lastname: Varlet
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging* / Q000473:pathology*; D001932:Brain Neoplasms / Q000145:classification* / Q000175:diagnosis / Q000401:mortality; D005602:France; D005910:Glioma / Q000145:classification* / Q000175:diagnosis / Q000401:mortality; D006761:Hospitals; D006801:Humans; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D009837:Oligodendroglioma / Q000145:classification* / Q000175:diagnosis / Q000401:mortality; D012189:Retrospective Studies; D015996:Survival Rate; D014057:Tomography, X-Ray Computed